AAPL   264.51 (-3.29%)
MSFT   156.71 (-0.93%)
AMZN   1,832.56 (-2.75%)
CGC   17.88 (-3.04%)
NVDA   252.94 (+0.13%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.20 (-4.28%)
ACB   1.34 (-7.58%)
F   6.78 (-2.73%)
BAC   27.81 (-4.53%)
GILD   67.79 (-6.70%)
DIS   114.40 (-3.08%)
AAPL   264.51 (-3.29%)
MSFT   156.71 (-0.93%)
AMZN   1,832.56 (-2.75%)
CGC   17.88 (-3.04%)
NVDA   252.94 (+0.13%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.20 (-4.28%)
ACB   1.34 (-7.58%)
F   6.78 (-2.73%)
BAC   27.81 (-4.53%)
GILD   67.79 (-6.70%)
DIS   114.40 (-3.08%)
AAPL   264.51 (-3.29%)
MSFT   156.71 (-0.93%)
AMZN   1,832.56 (-2.75%)
CGC   17.88 (-3.04%)
NVDA   252.94 (+0.13%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.20 (-4.28%)
ACB   1.34 (-7.58%)
F   6.78 (-2.73%)
BAC   27.81 (-4.53%)
GILD   67.79 (-6.70%)
DIS   114.40 (-3.08%)
AAPL   264.51 (-3.29%)
MSFT   156.71 (-0.93%)
AMZN   1,832.56 (-2.75%)
CGC   17.88 (-3.04%)
NVDA   252.94 (+0.13%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.20 (-4.28%)
ACB   1.34 (-7.58%)
F   6.78 (-2.73%)
BAC   27.81 (-4.53%)
GILD   67.79 (-6.70%)
DIS   114.40 (-3.08%)
Log in

NASDAQ:XNCR - Xencor Stock Price, Forecast & News

$32.79
+0.60 (+1.86 %)
(As of 02/28/2020 10:45 AM ET)
Today's Range
$31.55
Now: $32.79
$33.25
50-Day Range
$32.09
MA: $35.51
$37.77
52-Week Range
$27.75
Now: $32.79
$46.33
Volume4,324 shs
Average Volume262,105 shs
Market Capitalization$1.87 billion
P/E Ratio72.87
Dividend YieldN/A
Beta1.39
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.70 million
Book Value$10.42 per share

Profitability

Net Income$-70,410,000.00

Miscellaneous

Employees156
Market Cap$1.87 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.


Xencor (NASDAQ:XNCR) Frequently Asked Questions

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) posted its earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.52) by $0.05. The biopharmaceutical company earned $3.52 million during the quarter, compared to the consensus estimate of $6.73 million. Xencor had a net margin of 17.15% and a return on equity of 4.23%. View Xencor's Earnings History.

When is Xencor's next earnings date?

Xencor is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Xencor.

What price target have analysts set for XNCR?

11 brokers have issued twelve-month price objectives for Xencor's shares. Their forecasts range from $21.00 to $67.00. On average, they anticipate Xencor's stock price to reach $44.53 in the next year. This suggests a possible upside of 35.8% from the stock's current price. View Analyst Price Targets for Xencor.

What is the consensus analysts' recommendation for Xencor?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:
  • 1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (1/25/2020)
  • 2. Nomura analysts commented, "‘18087 (SSTR2xCD3) 2H19 to 1H20, 0 Est ASCO as Expected. SSTR2 is a validated target in NET and GIST, but these are solid tumors and suffer from tumor microenvironment effects and potential on-target toxicities. ‘18087 (SSTR2xCD3) is now the only bispecific in XNCR’s platform that we currently value. NVS to Our View. Recall, the clinical hold lifted in April; dosing to resume in coming weeks, but “tunable potency” still in question. Last update on clinicaltrials.gov was May 2 and included a Aug 2019 study completion date – we anticipate with appropriate study completion, NVS will return rights. More p 3. Checks – XNCRs’s Bispec C max -Dependent with Redesign." (8/8/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $40. Xencor reported 1Q 2019 earnings and offered a Business Update. No Ultromaris royalties were booked because they are booked ~1-2 quarters in arrears vs. Alexion. The company did have $112M in revenue from February’s Genentech deal, resulting in positive EPS for the quarter. Ultromaris and MOR208 revenues remain fast-approaching, near-term revenue opportunities. Alexion (ALXN: NC) reported $25M in Ultromaris sales in 1Q 2019. Xencor receives a low-single-digit royalty on these revenues; we model a 2% royalty." (5/12/2019)

Has Xencor been receiving favorable news coverage?

Media coverage about XNCR stock has been trending extremely negative on Friday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xencor earned a media sentiment score of -4.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Xencor.

Are investors shorting Xencor?

Xencor saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 5,150,000 shares, an increase of 6.8% from the January 30th total of 4,820,000 shares. Based on an average daily trading volume, of 337,300 shares, the short-interest ratio is presently 15.3 days. Approximately 9.2% of the shares of the stock are sold short. View Xencor's Current Options Chain.

Who are some of Xencor's key competitors?

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), Exelixis (EXEL), Fossil Group (FOSL), Apollo Global Management (APO), Immunomedics (IMMU), Intel (INTC), Abercrombie & Fitch (ANF) and Ciena (CIEN).

Who are Xencor's key executives?

Xencor's management team includes the folowing people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
  • Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations

Who are Xencor's major shareholders?

Xencor's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (3.50%), Geode Capital Management LLC (1.21%), Goldman Sachs Group Inc. (1.03%), Loomis Sayles & Co. L P (1.03%) and Bank of New York Mellon Corp (0.96%). Company insiders that own Xencor stock include Bassil I Dahiyat, Edgardo Baracchini Jr, Edgardo Baracchini, Jr, John J Kuch, John R Desjarlais, John S Stafford III and Paul A Foster. View Institutional Ownership Trends for Xencor.

Which major investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, PNC Financial Services Group Inc., Franklin Resources Inc., Rafferty Asset Management LLC, First Trust Advisors LP, Citigroup Inc., Arizona State Retirement System and Bank of America Corp DE. Company insiders that have sold Xencor company stock in the last year include John J Kuch, John R Desjarlais and John S Stafford III. View Insider Buying and Selling for Xencor.

Which major investors are buying Xencor stock?

XNCR stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Man Group plc, Raymond James & Associates, Los Angeles Capital Management & Equity Research Inc., Great West Life Assurance Co. Can, Panagora Asset Management Inc. and DCF Advisers LLC. View Insider Buying and Selling for Xencor.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $32.79.

How big of a company is Xencor?

Xencor has a market capitalization of $1.87 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $-70,410,000.00 in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe.View Additional Information About Xencor.

What is Xencor's official website?

The official website for Xencor is http://www.xencor.com/.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]


MarketBeat Community Rating for Xencor (NASDAQ XNCR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  704
MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe XNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Depreciation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel